^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD137 agonist

    Related drugs:
    1d
    Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=330, Recruiting, I-Mab Biopharma US Limited | N=168 --> 330 | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Enrollment change • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • CLDN18 (Claudin 18)
    |
    CLDN18.2 positive
    |
    Opdivo (nivolumab) • Imfinzi (durvalumab) • givastomig (TJ-CD4B)
    4d
    BP41072: A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov)
    P1/2, N=498, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule)
    |
    Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • Columvi (glofitamab-gxbm) • englumafusp alfa (RG6076)
    9d
    Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2) (clinicaltrials.gov)
    P2, N=180, Recruiting, I-Mab Biopharma US Limited
    New P2 trial • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CLDN18 (Claudin 18)
    |
    PD-L1 expression • CLDN18.2 positive
    |
    Opdivo (nivolumab) • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • givastomig (TJ-CD4B)
    10d
    YH32367-101: Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor (clinicaltrials.gov)
    P1/2, N=147, Recruiting, Yuhan Corporation | Trial completion date: Dec 2026 --> Apr 2028 | Trial primary completion date: Oct 2026 --> Mar 2028
    Trial completion date • Trial primary completion date • First-in-human
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    cisplatin • nesfrotamig (ABL105)
    13d
    Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors. (PubMed, Cancer Res Commun)
    This open-label, 4-part, phase 1 study evaluated INBRX-105 alone or with pembrolizumab in adults with locally advanced/metastatic, unresectable solid tumors (NCT03809624). Unfortunately, clinical development of INBRX-105 was ended because of hepatotoxicity and limited efficacy. Novel treatment combinations with nonredundant, complementary immunotherapies are needed.
    P1 data • Journal • First-in-human
    |
    PD-L1 (Programmed death ligand 1) • TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    Keytruda (pembrolizumab) • enristomig (INBRX-105)
    14d
    RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis (clinicaltrials.gov)
    P1/2, N=12, Active, not recruiting, Cabaletta Bio | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    LRP4 (LDL Receptor Related Protein 4)
    |
    cyclophosphamide • fludarabine IV
    16d
    STA101JG: A Phase I study of STA551 and STA551 in combination with atezolizumab in patients with solid tumours (2023-508764-30-00)
    P1, N=30, Active, not recruiting, Chugai Pharmaceutical Co. Ltd. | -> Active, not recruiting | Phase classification: PN/A --> P1
    Enrollment closed • Phase classification
    |
    Tecentriq (atezolizumab) • STA551
    17d
    RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy (clinicaltrials.gov)
    P2/3, N=74, Recruiting, Cabaletta Bio | Phase classification: P1/2 --> P2/3 | N=24 --> 74
    Phase classification • Enrollment change
    |
    cyclophosphamide • fludarabine IV
    17d
    BNT314-02: A clinical study to test if an investigational treatment called BNT314 when used in combination with another investigational treatment BNT327 and chemotherapy is beneficial and safe for patients with advanced colorectal cancer (2025-521768-36-00)
    P1/2, N=168, Recruiting, BioNTech SE
    New P1/2 trial
    |
    MSI (Microsatellite instability)
    |
    pumitamig (BNT327)
    17d
    GCT1046-07: Study of the Effectiveness and Safety of Acasunlimab Alone or With Pembrolizumab in treating Advanced Melanoma of the Skin That Has Returned After or did not respond to Cancer Immunotherapy (ABBIL1TY MELANOMA-07) (2025-520468-16-00)
    P1/2, N=129, Completed, Genmab A/S
    New P1/2 trial • Checkpoint inhibition
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    Keytruda (pembrolizumab) • acasunlimab (GEN1046)
    22d
    A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer (clinicaltrials.gov)
    P1/2, N=220, Recruiting, Nanjing Leads Biolabs Co.,Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Loqtorzi (toripalimab-tpzi) • albumin-bound paclitaxel
    23d
    PHGDH knockdown activates autophagic flux to suppress migration and invasion of gastric cancer cells. (PubMed, Transl Cancer Res)
    Notably, PHGDH downregulation may indirectly promote the assembly of the ULK1 complex through the concomitant upregulation of FIP200 and ATG101, thereby initiating autophagy. These data suggest that PHGDH plays a role in the progression of GC and may be considered a potential therapeutic target upon further confirmation in larger clinical studies.
    Journal
    |
    HIF1A (Hypoxia inducible factor 1, alpha subunit) • PHGDH (Phosphoglycerate Dehydrogenase)
    |
    xirestomig (ATG-101)